Guide
Your First Month on Tirzepatide: What Labelling Says to Expect
The first four weeks are the initiation dose, which approved labelling states is not a maintenance dosage. Judging the drug on month one judges it at a dose it is not mea
The first four weeks are the initiation dose, which approved labelling states is not a maintenance dosage. Judging the drug on month one judges it at a dose it is not meant to work at — and it is also the month a dose-tiered pricing plan charges you least.
This describes what approved labelling and the trials say about the first weeks. It is not a dosing instruction and not a protocol. Your prescriber sets your regimen.
What does labelling say about the first four weeks?
| Field | What labelling and the trials say |
|---|---|
| Dose | The initiation dose, not approved as a maintenance dosage |
| Purpose | Tolerability, not therapeutic effect |
| Most common effect | Nausea, about 29% at the highest dose across SURMOUNT-1 |
| When effects cluster | In the days after the dose is started or increased |
| Next step | An increase as tolerated, decided by your prescriber |
Why is month one a bad guide to the drug?
The trial curve is shallow early and steepest after a maintenance dose is reached, roughly five to six months in. Expecting month-one results at a month-one dose is expecting the drug to do something labelling does not claim it does yet.
Month one is also the month a dose-tiered plan charges least — typically $129 against a flat $186. So the cheapest month and the least effective month are the same month, and the plan that looks best in week four is usually the one that costs most by month twelve.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What is worth asking before month two?
- What will I pay at 10 mg on this plan?
- Who decides my next increase, and how quickly do they respond if a step is not tolerated?
- Which pharmacy filled this, and what is the beyond-use date on the vial?
- What is refunded if I stop during titration?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
What should I expect in the first month on tirzepatide?
The first four weeks are the initiation dose, which labelling states is not a maintenance dosage. Gastrointestinal effects cluster in the days after starting, and nausea is the most common.
Why is weight loss slow in month one?
The trial curve is shallow early and steepest after a maintenance dose is reached, roughly five to six months in. Month one is at a dose labelling calls initiation.
Is the cheapest month a good guide to a plan's cost?
No. On dose-tiered plans month one is the cheapest month, and the plan that looks best in week four is usually the one that costs most by month twelve.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Ro Body vs Hims & HersComparisons
- Hims & Hers vs Henry MedsComparisons
- Brand-Name vs Compounded TirzepatidePillar / Money
- Hims & Hers Tirzepatide ReviewProviders
- Zepbound vs MounjaroComparisons
- Tirzepatide Cost in 2026Pillar / Money
- Ro Body Tirzepatide ReviewProviders
Related coverage
GLP-1 Tirzepatide Rank. “Your First Month on Tirzepatide: What Labelling Says to Expect.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-first-month-what-to-expect-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.